Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
MRI and PET to Assess Pembrolizumab Response
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
- Status
- COMPLETED
- Phase
- PHASE2
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Pembrolizumab and Palliative Radiotherapy in Lung
- Status
- COMPLETED
- Phase
- PHASE1
Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Untreated Extensive SCLC
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
- Status
- TERMINATED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
- Status
- TERMINATED
- Phase
- PHASE3
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)
- Status
- TERMINATED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
- Status
- COMPLETED
- Phase
- PHASE3